A novel type of immunoblocking as a means to cure autoimmune diseases
|Coordinator||GU HOLDING AB - Holdingbolaget vid Göteborgs universitet AB|
|Funding from Vinnova||SEK 1 100 000|
|Project duration||April 2009 - April 2012|
Purpose and goal
We have developed unique tolerance inducing therapy for treatment of autoimmune disease and allergy, but focused on therapy against rheumatoid arthritis (RA). Current parts of the project involves investigations of the demands that contract research manufacturers may have, conduct animal studies to prepare for clinical studies, develop pharmacokinetic information, compare the treatment to established therapies and taking in experts to develop preclinical, toxicology and clinical programs. And finally to seek business collaboration, soft funding as well as venture capital.